A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Trial Profile

A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs PSA-IL2-GM-CSF vaccine (Primary) ; Interleukin-2
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Oncobioimune
  • Most Recent Events

    • 05 Dec 2017 Status changed from active, no longer recruiting to completed according to an OncBioMune Pharmaceuticals media release.
    • 05 Dec 2017 Results from patients completing 31-week post-therapy exam presented in a OncBioMune Pharmaceuticals media release.
    • 13 Nov 2017 Progression results at 19 weeks for all 20 patients, who have completed 6 vaccines, published in the OncBioMune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top